Review
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.
Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T et al.
ReviewCancer2025
Research Facts
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.
Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T et al.
Review · Moderate · 2025
Findings

PubMed study on Polysorbate 20 in cosmetics/dermatology

Design
Review
Evidence
Moderate
Journal
Cancer